Recombinant human neolaurin is a recombinant genetic engineering product of DNA. It is expressed and purified by E.coli, added with a proper amount of protein protectant and excipient, and freeze-dried into powder for injection, which is used to treat moderate and severe heart failure. According to the classification of pharmacological action, it belongs to drugs for treating heart failure. Composition and properties: each branch contains 0.25 mg of recombinant human angiopoietin as the main component, and the dressing is human albumin, as well as appropriate mannitol and phosphate. This product is a white or white-like freeze-dried block or powder. Specification: 0.25mg/ bottle. Usage and dosage This product is for intravenous injection. Before use, add sterilized water for injection (0.25mg/ bottle 1ml) to dissolve, and then add 5% glucose injection or sterilized normal saline (20ml). Suggested course of treatment: once a day for 5 consecutive days. Principle (including patent) Dr. Zhou Mingdong, the chief scientist of Shanghai Zesheng Technology Development Co., Ltd., has been engaged in the research on the molecular mechanism of heart development for a long time in the famous heart research institutes in the United States and Australia, and found the signal molecules involved in regulating the development, differentiation and function of myocardial cells, thus applying for world invention patents, and successively applying for patents in the process of product development. At the cellular level, it is found that recombinant human Newgranger can make the disordered cardiac myocyte structure orderly and strengthen the intercalated disc connection between myocardial cells. Animal pharmacodynamic experiments show that recombinant human neolaurin can reduce the damage degree of myocardial cells caused by ischemia, hypoxia, virus infection and other factors, repair the damaged myocardial cell structure and improve cardiac hemodynamics. Decrease renin activity and angiotensin II and aldosterone levels. Indications for the treatment of advanced heart failure and dilated cardiomyopathy. Pharmacological model tests of subacute and chronic heart failure in rats, viral myocarditis in mice, toxic myocarditis in mice induced by adriamycin, and congestive heart failure caused by inferior vena cava stenosis in dogs all show that recombinant human neolanglin can improve the damaged myocardial tissue structure, reduce the degree of ischemia and hypoxia, improve cardiac function, improve hemodynamics, significantly improve the survival rate of model animals, and effectively treat animal heart failure caused by various reasons. The safe recombinant human neolanglin has no effect on the cardiovascular and respiratory functions of monkeys. In the single dose acute toxicity test of mice, the lowest lethal dose was 35mg/kg, which was 3000 times of the clinical dose. The safety evaluation test of repeated administration in monkeys found that high dose of recombinant human neogranin could cause local vascular leakage in animals, and no obvious toxic and side effects were found in middle and low doses, which indicated that it had a certain safe dose range.